Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Bullboard Posts
Post by bjhernonon Mar 24, 2010 11:03am
287 Views
Post# 16918110

Arrangement Completed

Arrangement Completed

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of

the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

NEWS RELEASE

Bard Ventures Ltd. & Beatrix Ventures Inc.

Suite 800-1199 West Hastings Street

Vancouver, B.C., V6E 3T5

Tel.: (604) 687-2038 Fax: (604) 687-3141

March 15, 2010 TSX Venture Symbol: CBS

CNSX Symbol: BXV

ARRANGEMENT COMPLETED

Vancouver, BC, Canada: Bard Ventures Ltd. (“Bard”) (TSX.V: CBS) and Beatrix Ventures Inc.

(“Beatrix”) (CNSX: BXV) announce that further to the news releases of Bard dated October 9, 2009 and March 9, 2010, the Plan of Arrangement, which resulted in the Opikeigen Gold Property and $250,000 cash being transferred from Bard to Beatrix, closed on March 15, 2010, the effective date of the Arrangement.

Beatrix begins trading today, March 15, 2010, on the CNSX under the symbol BXV.

Under the Plan of Arrangement, persons who were registered as shareholders of Bard on March 15, 2010 will be entitled to receive one common share of Beatrix for every 10 Bard common shares held by them.  This provides the Bard shareholders with continued exposure to each company’s potential upside, additional growth opportunities and anticipated higher capital markets valuations for the two distinct asset bases. The Beatrix share certificates are expected to be mailed to Bard shareholders on or about March 19, 2010.

Bard’s Opikeigen Gold Property will now be held by Beatrix. This Arrangement will allow Bard to focus its resources on the Lone Pine Molybdenum Property while Beatrix can aggressively pursue the advancement of its base metal Opikeigen Gold Property.

On behalf of:

Bard Ventures Ltd.

“Eugene Beukman”

Eugene Beukman, President

Follow us on Twitter at https://twitter.com/bardventures

Join the Molybdenum Group on Facebook https://www.facebook.com/group.php?gid=113244697106

Become a Bard Ventures Fan on Facebook at https://www.facebook.com/home.php?#/pages/Bard-

Ventures/88081448028?ref=nf

For further information please visit our website at www.bardventures.com

This release includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements in this release, other than statements of historical facts, that address future production, reserve potential, exploration and development activities and events or developments that the Company expects, are forward-looking statements. Although management believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results or developments may differ materially from those in the forward-looking statements.  Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploration and development successes, continued availability of capital and financing, and general economic, market or business conditions. Please see our public filings at www.sedar.com for further information.

Bullboard Posts